MetaVia Inc. cotiza a 1.43 USD y tiene una capitalización bursátil de $9M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for…
| Periodo | 2026-08 | 2026-05 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.90 | $-0.79 | $-1.54 | $-2.86 |
| Estimado | $-0.82 | $-0.75 | $-2.75 | $-2.46 |
| Sorpresa | -9.8% | -5.3% | +44.0% | -16.3% |
| Métrica | MTVA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -243.3% | -40.4% | -202.9% |
| ROA | -116.6% | -32.0% | -84.6% |
| Current Ratio | 1.93 | 2.84 | -0.91 |
| Debt / Equity | — | 0.28 | — |